Table 3. Percentage of participants reporting SAEs classified by MedDRA primary organ class and preferred term over 14 months follow-up.

	Engerix-B (N = 107)			RTS,S/AS02D (N = 107)
	n	%	95% CI	n	%	95% CI
Number of subjects with at least one SAE reported	34	31.8	23.1–41.5	35	32.7	24.0–42.5
Number of SAEs reported classified by MedDRA preferred term*	82	76.6	67.5–84.3	75	70.1	60.5–78.6

N  =  number of subjects with at least one administered dose and included in ITT cohort.

n/%  =  number/percentage of subject reporting at least once the symptom.

*Symptoms reported by a subject after a given dose and classified by the same Preferred Term are counted once.